重酒石酸卡巴拉汀贴片与胶囊对阿尔茨海默病患者日常生活活动的影响。
Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer's disease.
机构信息
Department of Neurology & Psychiatry, St Louis University School of Medicine, MO, USA.
出版信息
Am J Alzheimers Dis Other Demen. 2011 Feb;26(1):65-71. doi: 10.1177/1533317510391240.
BACKGROUND
Rivastigmine patches provide similar efficacy to rivastigmine capsules with a lower incidence of gastrointestinal side effects in patients with probable Alzheimer's disease (AD).
METHODS
Post hoc analysis of a 24-week, prospective, international, randomized, double-blind, placebo- and active-controlled trial. Patients (n = 892) with probable AD received rivastigmine transdermal patches (9.5 mg/24 hours [10 cm(2)]), rivastigmine capsules (6 mg twice daily), or placebo, and impact on activities of daily living (ADLs) was assessed utilizing 3 subscales: basic, high-level function, and autonomy.
RESULTS
At week 24, both rivastigmine groups demonstrated significantly superior performance in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Total Score versus placebo (rivastigmine patch, P = .013; capsules, P = .039). Overall, both rivastigmine formulations provided benefits in ADL subscales. For basic ADLs, rivastigmine capsules performed significantly better than placebo (P = .012). For high-level function ADLs, rivastigmine patch performed better than placebo (P = .056). For autonomy ADLs, rivastigmine patch performed significantly better than placebo (P = .017).
CONCLUSION
Rivastigmine patches and capsules provide significant effects in both total and subscale ADLs in patients with probable AD.
背景
与利伐斯的明胶囊相比，利伐斯的明贴片在可能患有阿尔茨海默病（AD）的患者中具有相似的疗效，且胃肠道副作用发生率更低。
方法
对一项为期 24 周、前瞻性、国际性、随机、双盲、安慰剂对照和活性对照试验进行事后分析。有可能性 AD 的患者（n=892）接受利伐斯的明透皮贴片（9.5 毫克/24 小时[10 平方厘米]）、利伐斯的明胶囊（6 毫克，每日两次）或安慰剂治疗，并利用日常生活活动（ADL）的 3 个亚量表评估对其的影响：基本、高级功能和自主。
结果
在第 24 周，与安慰剂相比，利伐斯的明两组在阿尔茨海默病合作研究-日常生活活动（ADCS-ADL）总分方面均表现出明显的优越性（利伐斯的明贴片，P=0.013；胶囊，P=0.039）。总体而言，两种利伐斯的明制剂在 ADL 亚量表中都提供了益处。对于基本的 ADL，利伐斯的明胶囊的表现明显优于安慰剂（P=0.012）。对于高级功能 ADL，利伐斯的明贴片的表现优于安慰剂（P=0.056）。对于自主 ADL，利伐斯的明贴片的表现明显优于安慰剂（P=0.017）。
结论
利伐斯的明贴片和胶囊在可能患有 AD 的患者中对总 ADL 和亚量表 ADL 均有显著作用。
Zotero 插件